Indicated for: prostate cancer
Route of administration: infusion
Substance: cabazitaxel (taxane antineoplastic)
ATC: L01CD04 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes)
Cabazitaxelum is a medication used for the treatment of metastatic castration-resistant prostate cancer, particularly in patients previously treated with docetaxel. It is a chemotherapeutic agent from the taxane class that interferes with microtubule function, inhibiting cell division and causing cancer cell death.
The medication is administered via intravenous infusion, usually once every three weeks, in combination with prednisone, as directed by a doctor. The treatment requires close monitoring to manage side effects and assess the patient's response.
Common side effects include fatigue, nausea, diarrhea, decreased blood cell counts, and hair loss. In rare cases, severe adverse effects such as febrile neutropenia or allergic reactions may occur.
Cabazitaxelum is not recommended for pregnant or breastfeeding women. Patients should inform their doctor about all medications they are taking to avoid drug interactions.